Peptide vaccines use short, lab-made pieces of a protein to train the immune system to recognize a virus or a cancer cell. The quick answer: no standalone synthetic peptide vaccine is FDA-approved for cancer or infection as of October 2026. A melanoma peptide vaccine improved response rates (16% vs 6%) in one phase 3 trial,[2] but large trials in pancreatic and kidney cancer failed to extend survival.[3][4]
This page is part of our peptide basics hub. For how lab-made peptides relate to natural ones, see natural vs synthetic peptides.
Bottom line
- Established: peptide vaccines can trigger measurable T-cell responses with mostly mild side effects.[1]
- Mixed: one positive phase 3 cancer result (melanoma) against several negative ones.[2][3][4]
- Promising: personalized neoantigen vaccines and survivin vaccines in brain cancer, based on small early trials.[5][6]
- Cautionary: an Alzheimer’s peptide vaccine caused brain inflammation.[7]
How peptide vaccines work
Immune T cells don’t see whole proteins. They recognize short fragments, called epitopes, displayed on the surface of cells by HLA molecules. A peptide vaccine supplies those fragments directly, usually with an adjuvant (an immune booster) because peptides alone provoke only weak responses.[1]
Advantages include precise targeting, simple chemical manufacture and good stability. Drawbacks are weak immune activation, the need to match a person’s HLA type for short peptides, and the risk that tumors or viruses stop displaying the target.[1]
Key trials at a glance
| Vaccine | Disease | Design | Result |
|---|---|---|---|
| gp100 peptide + interleukin-2 | Advanced melanoma | Phase 3, 185 patients | Response 16% vs 6%; longer progression-free survival[2] |
| GV1001 (telomerase peptide) | Pancreatic cancer | Phase 3 (TeloVac), 1,062 patients | No survival benefit[3] |
| IMA901 (multi-peptide) | Kidney cancer | Phase 3 (IMPRINT), 339 patients | No survival benefit[4] |
| Personal neoantigen peptides | Melanoma | Phase 1, 6 patients | 4 of 6 recurrence-free at 25 months[5] |
| SurVaxM (survivin peptide) | Glioblastoma | Phase 2a, 64 patients | 95% progression-free at 6 months; no control group[6] |
| AN1792 (amyloid-beta peptide) | Alzheimer’s disease | Phase 2a, 372 patients | Halted; brain inflammation in 6%[7] |
| EpiVacCorona | COVID-19 | Phase 3, 3,000 volunteers | Developer reported 82.5% efficacy[8] |
Cancer vaccine trials
Melanoma (gp100). In a phase 3 trial of 185 patients with advanced melanoma, adding a gp100 peptide vaccine to high-dose interleukin-2 raised the response rate from 6% to 16% and lengthened median progression-free survival from 1.6 to 2.2 months. Median overall survival was 17.8 vs 11.1 months, a difference that fell just short of statistical significance.[2] The gains were real but modest, and only patients with a specific HLA type (HLA-A*0201) could take part.
Pancreatic cancer (TeloVac). The UK TeloVac trial randomized 1,062 patients to chemotherapy alone or chemotherapy plus GV1001, a peptide from the enzyme telomerase. Median survival was 7.9 months with chemotherapy alone, 6.9 months with sequential vaccine and 8.4 months with concurrent vaccine; adding the vaccine did not help.[3]
Kidney cancer (IMPRINT). IMA901 combined 10 tumor peptides. In 339 patients, adding it to the drug sunitinib did not improve survival (33.2 months vs not reached with sunitinib alone).[4]
Personalized neoantigen vaccines. Neoantigens are protein fragments created by mutations unique to a patient’s tumor, so the immune system sees them as foreign. In a 2017 phase 1 study, six melanoma patients each received up to 20 personalized peptides after surgery. The vaccine triggered T cells against many of the targets, and four of six patients had no recurrence 25 months later.[5] With only six patients and no control group, this shows feasibility, not benefit.
Glioblastoma (SurVaxM). SurVaxM targets survivin, a protein many tumors use to avoid cell death. In a single-arm phase 2a trial of 64 people with newly diagnosed glioblastoma, 95% of evaluable patients were progression-free at 6 months, median progression-free survival was 11.4 months and median overall survival 25.9 months. No serious side effects were attributed to the vaccine.[6] Without a comparison group, these numbers can’t be directly compared with standard treatment.
Alzheimer’s disease: a safety lesson
AN1792 was a vaccine made from the full amyloid-beta 42 peptide, the protein fragment that builds up in Alzheimer’s plaques. In a phase 2a trial of 372 patients, 18 of 298 vaccinated patients (6%) developed meningoencephalitis (inflammation of the brain and its lining), compared with none on placebo, and dosing was stopped.[7] The authors suspected a harmful T-cell response. Researchers have since explored vaccine designs meant to produce antibodies without that T-cell reaction, but none is approved.
COVID-19: EpiVacCorona
EpiVacCorona, developed by Russia’s state VECTOR center, uses synthetic peptide fragments of SARS-CoV-2 proteins. The developers describe it as the first synthetic peptide antiviral vaccine for mass immunization. Their phase 3 report in 3,000 volunteers, published in 2023, described mild reactions and 82.5% efficacy after two doses.[8] The data come from the developer, and the vaccine has not been authorized in the US or EU.
Limitations
- Many peptide vaccines only work in patients with matching HLA types, which narrows who can take part.
- Positive early-phase signals often vanish in randomized trials.
- Weak immune activation means results depend heavily on the adjuvant.[1]
What’s next
- Leukemia: REGAL, a phase 3 trial of galinpepimut-S (a WT1 peptide vaccine) as maintenance therapy in acute myeloid leukemia, enrolled 127 patients. The registry lists it as active but not recruiting, with primary completion set for December 2025; results had not been posted when we checked.[9]
- Glioblastoma: SURVIVE, a randomized phase 2 trial of SurVaxM in 247 planned patients, has an “unknown” status on the registry because it hasn’t been updated since February 2024.[10]
Peptides are also being attached to drugs and imaging agents; see peptide-drug conjugates and peptide radiotracers. Immune-signaling peptides such as thymosin alpha-1 work differently from vaccines; see its profile.
Questions to discuss with a clinician
- Is there a vaccine trial for my cancer type, and do I qualify based on HLA type?
- What would a trial vaccine add to my standard treatment?
- What side effects were seen in earlier studies?
- How would I be monitored during a trial?
